Cargando…
Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition
Dipeptidyl peptidase‐4 (DPP‐4) inhibition is a glucose‐lowering medication for type 2 diabetes. It works through stimulation of insulin secretion and inhibition of glucagon secretion in a glucose‐dependent manner, resulting in lowered fasting and postprandial glycemia with low risk of hypoglycemia....
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264410/ https://www.ncbi.nlm.nih.gov/pubmed/33949781 http://dx.doi.org/10.1111/jdi.13564 |